

**DH Inpatient & Outpatient Urine 2025
(MHMH, APD, NLH, Southern Clinics)**



To obtain a sound statistical estimate of cumulative %S rates, organisms are included only when there are 30 or more unique patient isolates tested. Unless otherwise noted, data represents calendar year 2025.

	Number of Isolates	Penicillin	Ampicillin	Ox/Nafcillin	Piperacillin/Tazo	Cefazolin (first)	Ceftazidime (third)	Ceftriaxone (third)	Cefepime (fourth)	Gentamicin	Tobramycin	Vancomycin	Trimethoprim-sulfa	Ciprofloxacin	Levofloxacin	Nitrofurantoin
GRAM POSITIVES																
<i>Staphylococcus aureus</i> - ALL¹	193			76		76				98 ²		100	91			99
-<i>Staphylococcus aureus</i> - MSSA	147			100		100				99 ²		100	94			99
-<i>Staphylococcus aureus</i> - MRSA	46			0		0				95 ²		100	78			97
<i>Enterococcus faecium</i>	102	17	19			0 ^I	0 ^I	0 ^I	0 ^I			48			17	14
<i>Enterococcus faecalis</i>	899	99	100			0 ^I	0 ^I	0 ^I	0 ^I			98			88	99
GRAM NEGATIVES																
<i>Citrobacter freundii</i> complex	129		0 ^I		84	0 ^I		78	98 ³	90			86	85	83	91
<i>Citrobacter koseri</i>	71		0 ^I		95	94		100	100 ³	100			100	100	100	90
<i>Enterobacter cloacae</i> complex	242		0 ^I		75	0 ^I		48 ⁴	97 ⁵	99			92	97	95	43
<i>Escherichia coli</i>	5792		64		97	92 ⁷		94	97 ⁶	93			83	83	84	97
<i>Klebsiella</i> (prev. <i>Enterobacter</i>) <i>aerogenes</i>	106		0 ^I		84	0 ^I		84	100 ³	100			99	96	95	14
<i>Klebsiella oxytoca</i>	223		0 ^I		93	8		95	99 ⁶	98			94	94	95	86
<i>Klebsiella pneumoniae</i>	1034		0 ^I		93	92 ⁷		93	96 ⁶	97			90	88	88	32
<i>Morganella morganii</i>	96		0 ^I		97	0 ^I				92			84	82	80	0 ^I
<i>Proteus mirabilis</i>	444		84		100	95 ⁷		99	99 ⁶	93			89	90	90	0 ^I
<i>Providencia rettgeri</i>	30		0 ^I		96	0 ^I		100	96 ⁶	100			93		76	0 ^I
<i>Serratia marcescens</i>	58		0 ^I			0 ^I		96	100 ³	100			100	98	98	0 ^I
<i>Pseudomonas aeruginosa</i>	318		0 ^I		93		94	0 ^I	95		98		0 ^I	86	84	

¹ MRSA rate = 24% of all *Staphylococcus aureus* isolates from DH inpatient & outpatient (MHMH/APD/NLH/Southern Clinics) urine sources.

² Gentamicin should not be used for monotherapy for gram-positive bacteria.

³ Percentage accounts for isolates that test S + SDD. Zero isolates tested SDD.

⁴ *Enterobacter cloacae* complex and ceftriaxone: n=33

⁵ Percentage accounts for isolates that test S + SDD. 2% of isolates tested SDD for *E. cloacae* complex and cefepime.

⁶ Percentage accounts for isolates that test S + SDD. Less than 1% of isolates tested SDD for cefepime.

⁷ For *E. coli*, *K. pneumoniae*, and *P. mirabilis* causing uncomplicated UTIs, susceptibility to cefazolin can be used as a surrogate for cefpodoxime, cefuroxime and cephalexin.

^I Intrinsic resistance

For use by providers within the DH system only. Please do not share with pharmaceutical representatives.